Insights
USA Today Article - A Blood Test for Alzheimer’s? Yes — And Here’s Why It Matters
With Alzheimer’s disease affecting millions of Americans, clinicians need practical diagnostic tools. Blood‑based biomarkers are gaining attention as...
Medical Laboratory Observer (MLO) Article - From imaging to blood: Alzheimer’s diagnostics evolve
Alzheimer’s disease (AD) is the major cause of dementia worldwide that leads to morbidity, long‑term care utilization, and significant healthcare...
Integration of ADx NeuroSciences Within Fujirebio Unleashes a World of New Possibilities
Fujirebio Europe N.V. will formally and fully integrate ADx NeuroSciences N.V. into its organization on April 1, 2026. This completes a process that...
CAP Today Article - Alzheimer's blood tests poised to lead
For a pathology that is invariably associated with dimming—of memory, of relationships, of personality—
Alzheimer’s disease has been linked to...
When To Use Blood-Based Biomarkers For Alzheimer's Disease Assessment
Accelerating Alzheimer’s diagnosis with blood-based biomarker testing
Studies indicate that patients may wait an average of more than three years for...
How Can You Diagnose Alzheimer's at the Earliest Stages?
Diagnosing Alzheimer’s at the earliest stages
An early Alzheimer’s diagnosis has never been more important — or more attainable — than it is today...
The Future of Alzheimer's Disease Diagnosis
What is the future of Alzheimer's disease diagnosis?
Two anti-amyloid drugs are now available to patients with mild cognitive impairment (MCI) or mild...
Everything You Need to Know About Amyloid Presence and Alzheimer’s Disease-modifying Therapies
Confirming amyloid pathology before administering Alzheimer’s disease-modifying therapies.
Approximately seven million Americans are currently living...
Video - The Scientist Symposium: Understanding Disease Through Biomarkers
The Evolution of AD Diagnosis: The Role of Biomarkers
Biomarkers are transforming the landscape of disease detection and diagnosis—especially in the...